



**Luigia Elzi**

**Kontakt**

Luigia Elzi

## Publikationen (39)

Marzolini C, Cavassini M, Braun D, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, Elzi L, Swiss HIV Cohort Study S. Effect of SLC01B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen. *Br J Clin Pharmacol* 2023

Elzi L, Battegay M, Bernasconi E, Günthard H, Vernazza P, Calmy A, Cavassini M, Furrer H, Erb S. Adverse events of raltegravir and dolutegravir. *AIDS* 2017; 31:1853–1858.

Elzi L, Furrer H, Bernasconi E, Schmid P, Calmy A, Cavassini M, Fehr J, Patzen A, Conen A, Battegay M. Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. *Open Forum Infect Dis* 2016; 3:ofw022.

Babouee Flury B, Elzi L, Kolbe M, Frei R, Maja W, Schären S, Widmer A, Battegay M. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?. *BMC Infect Dis* 2014; 14:226.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. *PloS one* 2013; 8

Nüesch R, Bucher H, Battegay M, Calmy A, Thurnheer M, Vernazza P, Cavassini M, Weber R, Bernasconi E, Elzi L, Wang Q, Swiss HIV Cohort Study. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). *J Acquir Immune Defic Syndr* 2013; 62:396–404.

Boillat-Blanco N, Wandeler G, Fehr J, Daou S, Elzi L, Adami M, Strahm C, Osih R, Taffé P, Darling K, Cavassini M. Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study. *J Acquir Immune Defic Syndr* 2013; 62:180–9.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. *PloS one* 2012; 7:e50307.

Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Erb S, for the Swiss HIV Cohort Study. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. *Arch Intern Med* 2012:1–9.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Celleraï C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PloS one* 2012; 7:e37983.

Staehelein C, Furrer H, Bernasconi E, Schmid P, Cavassini M, Elzi L, Weber R, Calmy A, Keiser O, Swiss HIV Cohort Study. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2012; 59:79–85.

Boillat Blanco N, Cavassini M, Bertisch B, Weber R, Rauch A, Elzi L, Calmy A, Bernasconi E, Giulieri S, Da Costa V, Probst A, Bochud P. Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. *J Acquir Immune Defic Syndr* 2011; 58:472–4.

Elzi L, Bassetti S, Bernasconi E, Hoffmann M, Hirschel B, Cavassini M, Fehr J, Furrer H, Steffen I, Battegay M. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. *BMC Infect Dis* 2011; 11:319.

Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. *Clin Infect Dis* 2011; 53:1143-52.

Babouee Flury B, Elzi L, Frei R, Widmer A, Battegay M. A comment on Marschall et Al. *Clin Infect Dis* 2011; 53:748, author reply 748-9.

Nguyen A, Schmid P, Bernasconi E, Rauch A, Elzi L, Mello A, Cavassini M, Mercier I, Delhumeau C, Calmy A, Hirschel B. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). *AIDS* 2011; 25:1481-7.

Marzolini C, Elzi L, Battegay M, Khoo S, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Weber R, Back D, Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. *J Antimicrob Chemother* 2011; 66:2107-11.

Kenfak-Foguena A, Cavassini M, Izpopet J, Abravanel F, Moradpour D, Jost J, Gurter-De La Fuente V, Elzi L, Evison J, Kaiser L, Kovari H, Darling K, Witteck A, Bürgisser P, Schöni-Affolter F, Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland. Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. *Emerging Infect Dis* 2011; 17:1074-8.

Kaufmann G, Battegay M, Hirschel B, Bernasconi E, Vernazza P, Giulieri S, Furrer H, Weber R, Elzi L, Swiss HIV Cohort Study. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. *AIDS* 2011; 25:441-51.

Ortiz M, Tarr P, Telenti A, Günthard H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Elzi L, Arnedo M, Martinez R, Kovari H, Furrer H, Poloni E, Swiss HIV Cohort Study. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipotrophy. *J Infect Dis* 2011; 203:620-4.

Lubomirov R, Telenti A, Günthard H, Furrer H, Vernazza P, Elzi L, Bernasconi E, Hirschel B, Cavassini M, Martinez R, Ledergerber B, di Iulio J, Colombo S, the Swiss HIV Cohort Study. Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. *J Infect Dis* 2010; 203:246-257.

Rotger M, Tarr P, Telenti A, Egger M, Ledergerber B, Weber R, Furrer H, Hirschel B, Bernasconi E, Cavassini M, Vernazza P, Elzi L, Taffé P, Martinez R, Gsponer T, Swiss HIV Cohort Study. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. *Clin Infect Dis* 2010; 51:1090-8.

Hasse B, Weber R, Nicca D, Bernasconi E, Cavassini M, Elzi L, Evison J, Jeannin A, Glass T, Vernazza P, Hirschel B, Ledergerber B, Swiss HIV Cohort Study. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. *Clin Infect Dis* 2010; 51:1314-22.

Thurnheer M, Furrer H, Zwahlen M, Christen A, Bernasconi E, Schmid P, Elzi L, Cavassini M, Toutous-Trellu L, Weber R, Swiss HIV Cohort Study. Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. *AIDS* 2010; 24:1907-16.

Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Marzolini C, Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. *Archives of internal medicine* 2010; 170:57-65.

Ferry T, Calmy A, Schmid P, Bernasconi E, Elzi L, Weber R, Rauch A, Delhumeau C, Meylan P, Dang T, Hirschel B, Swiss HIV Cohort Study. Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2010; 50:115-8.

Marzolini C, Battegay M, Back D, Ledergerber B, Khoo S, Vernazza P, Calmy A, Bernasconi E, Cavassini M, Chave J, Furrer H, Fux C, Weber R, Gibbons S, Elzi L, Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. *Antivir Ther (Lond)* 2010; 15:413-23.

Khanna N, Hirsch H, Battegay M, Bernasconi E, Vernazza P, Fux C, Cavassini M, Garzoni C, Mueller N, Elzi L, Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 48:1459-66.

Elzi L, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Fux C, Weber R, Kaufmann G, Swiss HIV Cohort Study. Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. *HIV clinical trials* 2009; 10:207-14.

Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Simcock M, Rauch A, Swiss HIV Cohort Study. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. *Antiviral therapy* 2008; 13:1077-82.

Arnedo M, Tarr P, Telenti A, Beckmann J, Bergmann S, Darioli R, Bernasconi E, Vernazza P, Weber R, Elzi L, Hirschel B, Furrer H, Sahli R, Taffé P, Swiss HIV Cohort Study. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. *Pharmacogenetics and genomics* 2007; 17:755-64.

Ledergerber B, Weber R, Egger M, Schmid P, Bernasconi E, Cavassini M, Hirschel B, Elzi L, Lehmann R, Rickenbach M, Furrer H, Swiss HIV Cohort Study. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007; 45:111-9.

Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Wolbers M, Simcock M, Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. *Antiviral therapy* 2007; 12:1165-73.

Nicca D, Moody K, Elzi L, Spirig R. Comprehensive clinical adherence interventions to enable antiretroviral therapy: a case report. *The Journal of the Association of Nurses in AIDS Care : JANAC* 2007; 18:44-53.

Wunder D, Furrer H, Mueller B, Bernasconi E, Schmid P, Elzi L, Cavassini M, Hirschel B, Mueller N, Fux C, Bersinger N, Swiss HIV Cohort Study. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. *Antiviral therapy* 2007; 12:261-5.

Elzi L, Furrer H, Rickenbach M, Bernasconi E, Schmid P, Cavassini M, Hirschel B, Weber R, Schlegel M, Swiss HIV Cohort Study. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007; 44:94-102.

Keiser O, Aebi-Popp K, Bernasconi E, Schmid P, Elzi L, Zinkernagel A, Zellweger C, Chapuis-Taillard C, Wunder D, Martinez de Tejada B, Rickenbach M. Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study. *Journal of acquired immune deficiency syndromes (1999)* 2006; 43:550-5.

Elzi L, Spoerl D, Voggensperger J, Nicca D, Simcock M, Bucher H, Spirig R, Battegay M, Swiss HIV Cohort Study. A smoking cessation programme in HIV-infected individuals: a pilot study. *Antiviral therapy* 2006; 11:787-95.

Karrer U, Speck R, Weber R, Russotti M, Schmid P, Hirschel B, Gayet-Ageron A, Cavassini M, Battegay M, Elzi L, Furrer H, Ledergerber B, Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. *AIDS (London, England)* 2005; 19:1987-94.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)